Akzo Nobel shareholders approve dividend

Arnhem, the Netherlands, April 25, 2006 – Shareholders of Akzo Nobel (Euronext Amsterdam: AKZ; Nasdaq: AKZOY) today approved the 2005 annual accounts and approved the dividend for the 2005 financial year at EUR 1.20 (2004: EUR 1.20) per common share. This results in a dividend payment of EUR 343 million, representing a payout ratio of 36% relative to net income. An interim dividend of EUR 0.30 was paid in October 2005, which means the final dividend will be EUR 0.90 per share. The final dividend will be made payable from May 5, 2006, and Akzo Nobel shares will be traded ex-final dividend on Euronext Amsterdam from April 27, 2006. Changes in the Supervisory Board As of May 1, Maarten van den Bergh will become Chairman of Akzo Nobel’s Supervisory Board. He will succeed Aarnout Loudon, who will resign from the Supervisory Board as of the same date. His departure brings to an end a long and distinguished career with Akzo Nobel and the company wishes to express its gratitude and appreciation for his invaluable contribution. Mr Van den Bergh is Chairman of Lloyds Bank plc and a non-executive director of Royal Dutch Shell plc., BT Group and British Airways. Antony Burgmans - Chairman of Unilever N.V. and Unilever plc - and Louis R. Hughes - Chief Executive Officer of GBS Laboratories - were both appointed to the Supervisory Board for four-year terms, effective May 1, 2006. They succeed retiring Chairman Loudon and Lars Thunell, who resigned in November 2005 following his appointment to the World Bank. Karel Vuursteen and Alain Mérieux were both reappointed for another term. Not for publication – for more information Akzo Nobel nv Corporate Media Relations, tel. +31 26 366 43 43 Contact: Tim van der Zanden Note for the editor Akzo Nobel is a Global Fortune 500 company and is listed on both the Euronext Amsterdam and NASDAQ stock exchanges. It is also included on the Dow Jones Sustainability Indexes and FTSE4Good Index. Based in the Netherlands, we are a multicultural organization serving customers throughout the world with human and animal healthcare products, coatings, and chemicals. We employ around 61,500 people and conduct our activities in four segments − human and animal health, coatings and chemicals − subdivided into 13 business units, with operating subsidiaries in more than 80 countries. Consolidated revenues for 2005 totaled EUR 13.0 billion. The financial results for the second quarter will be published on July 20, 2006. Internet: www.akzonobel.com Safe Harbor Statement* This press release may contain statements which address such key issues as Akzo Nobel’s growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, progress of drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more comprehensive discussion of the risk factors affecting our business please see our Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the company’s corporate website www.akzonobel.com. The 2005 Annual Report on Form 20-F will be available at the end of the second quarter of 2006. * Pursuant to the U.S. Private Securities Litigation Reform Act 1995.